Mesothelioma Articles: Page 1 of 11

Clinical Trial of Imfinzi (Durvalumab) in Conjunction with Chemotherapy Yields Significantly Longer Survival Time for Patients Diagnosed with Malignant Pleural Mesothelioma

• July 28, 2020
• Isabella LiPuma
• Mesothelioma, Research, Treatments

Immuno-Oncology News recently published results of a Phase 2 clinical trial of the immuno-checkpoint inhibitor Imfinzi (durvalumab) for patients diagnosed with malignant pleural mesothelioma.  The PrECOG cancer research group tested the effects of pairing Imfinzi, an AstraZeneca drug that blocks the activity of the PD-1 receptor in immune T-cells, with standard chemotherapy on a group of 55 individuals who had been recently diagnosed with inoperable malignant pleural mesothelioma. The [...]

Continue reading

Pairing Machine Learning with PET Scans Can Help Predict Mesothelioma Outcomes

• July 24, 2020
• David Belsky
• Mesothelioma, Research, Treatments

The EJNMMI Research medical journal recently published an article entitled “FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients” that outlines a study wherein 72 patients diagnosed with malignant pleural mesothelioma (MPM) at the University Hospital Zurich underwent pre-treatment FDG PET and CT scans alongside curative treatments. In the study, Swiss researchers discovered that using machine-learning radiomics models in conjunction with PET scans to [...]

Continue reading

Mesothelioma Patients Can Safely Get Treatment Through Telehealth and Video

• July 14, 2020
• Lisa Hyde-Barrett
• Mesothelioma, Nurse's Corner, Patients, Treatments

The COVID-19 virus has disrupted all of our lives and routines. Things that we always did and places we always went are no longer available. The pandemic has forced us to all look at things we routinely do and challenged us to do them differently. Like in business, in medicine sometimes small disruptions can lead to larger innovative changes. In the treatment of malignant mesothelioma, disruptors have led the way. Over the years we have seen doctors challenging the previously held belief [...]

Continue reading

New Study Shows LMB-100 Can Be Even More Effective Paired with Keytruda for Mesothelioma Treatment

• July 10, 2020
• David Belsky
• Mesothelioma, Research, Treatments

A new study published by the Science Translational Medicine journal showed that, for a small cohort, LMB-100 could be even more effective when paired with Keytruda for treating patients with mesothelioma. Researchers saw a median survival rate of almost a year, with a handful of clinical trial participants continuing to show progress after more than three years. Following this success, the National Cancer Institute is currently accepting clinical trial participants for phase 2 of the study. [...]

Continue reading

Keytruda Approved by FDA for Further Potential Treatments of Mesothelioma

• July 2, 2020
• David Belsky
• Mesothelioma, Research, Treatments

Keytruda, an antibody drug used in cancer immunotherapy manufactured by Merck and also known as Pembrolizumab, has been approved by the FDA for treatment of solid tumor cancers. Previously, the drug had only been approved to treat non-small cell lung cancer. This is an important development for certain mesothelioma patients. In a press release, the FDA said that clinical trials showed an effective response rate for 29 percent of patients with mesothelioma and other applicable tumors that [...]

Continue reading

• Next